Search - Prime Therapeutics
-
Expert Clinical Network Insights Hemophilia December 17, 2024 Medication insights: marstacimab-hncq (Hympavzi) The U.S. Food and Drug Administration (FDA) approved marstacimab-hncq (Hympavzi) in...
-
publications Drug Approvals: February 2025 Monthly update on newly approved specialty and traditional drugs, new indications and first-time generic launches February 28, 2025 Specialty New drugs...
-
publications High-Cost Therapy Profile: May 2025 Vusolimogene oderparepvec Intratumoral | Replimune Oncology-Gene therapy May 15, 2025 Proposed indications Advanced melanoma FDA approval...
-
PUBLICATIONS FDA Decisions Expected: February 2025 Drug pipeline for February 2025 January 15, 2025 Your monthly synopsis of new drugs expected to hit the market At Prime Therapeutics (Prime), we...